Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Pharmacokinetics of Engasertib in Participants With and Without Hepatic Impairment

9. november 2026 opdateret af: Vaderis Therapeutics AG

A Phase 1, Open-label, Parallel Cohort Study to Compare the Pharmacokinetics of Engasertib in Adult Participants With Mild to Moderate Hepatic Impairment Relative to Participants Without Hepatic Impairment

The main objective of this trial is to compare the pharmacokinetics (PK) of engasertib in plasma following administration of a single oral dose in adult participants with mild to moderate hepatic impairment relative to age- and body weight-matched participants without hepatic impairment.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

18

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Vaderis Therapeutics AG
  • Telefonnummer: +1 844-823-3747
  • E-mail: info@vaderis.com

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age of 18 to 70 years (both inclusive), at the time of signing the informed consent.
  • Body weight ≥ 50 kg and a body mass index (BMI) within the range 18 to 35 kg/m^2 (both inclusive) at screening.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
  • Non-smoker, former smoker or stable non-smoker for at least 3 months prior to screening. Participants must also have abstained from use of other nicotine containing products for at least 3 months before screening.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol prior to any clinical trial specific procedure.

Participants without hepatic impairment (Cohort 1) only:

  • Overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and electrocardiogram (ECG).
  • Clinically acceptable results of clinical chemistry, hematology, coagulation, and urinalysis at screening.
  • No known or suspected hepatic impairment; including at screening, meet all the following criteria, as assessed by central laboratory: a) alanine aminotransferase (ALT) ≤ 1.1 x upper limit of normal (ULN); b) aspartate aminotransferase (AST) ≤ 1.2 x ULN; c) Total serum bilirubin ≤ 1.2 x ULN; d) Serum albumin ≥ lower limit of normal (LLN); e) Prothrombin time ≤ 1.2 x ULN.
  • Participant meets the demographic-matching criteria, including body weight (kg) ± 20 % and age ± 15 years of the average of the pooled hepatic impairment cohorts (Cohorts 2 and 3). Attempts will be made to ensure that the male-to-female distribution in Cohort 1, is comparable (i.e., ± 1) to that in the pooled hepatic impairment cohorts (Cohorts 2 and 3).

Participants with impaired hepatic function (Cohorts 2 and 3 only):

  • Documented diagnosis of hepatic impairment that meets the criteria for Class A or B of the Child-Pugh classification, with no clinically significant change in disease status within the 28 days prior to the screening visit, as documented by the participant's recent medical history (e.g., no worsening clinical signs of hepatic impairment, no worsening of total bilirubin or prothrombin time by more than 50%).
  • Participant is willing and able to abide by the lifestyle guidelines described in the protocol.

Exclusion Criteria:

  • Clinically relevant medical condition or malignancy that may significantly alter the absorption, metabolism or elimination of engasertib, constitute a safety risk, or interfere with interpretation of trial results.
  • History or evidence of malabsorption, or gastrointestinal surgery or disease that may significantly affect the absorption, distribution, metabolism or excretion of engasertib.
  • Known or suspected hypersensitivity to engasertib or any component of its formulation.
  • Clinically significant infection or immunodeficiency, including relevant active viral infection.
  • Use of prohibited concomitant medications or therapies that may interfere with the pharmacokinetics of engasertib within the protocol-defined period before dosing.
  • Use of another investigational drug or participation in another clinical trial within 30 days or 5 half-lives of the prior trial intervention, whichever is longer.
  • Clinically significant abnormalities in vital signs, ECG, or renal function that preclude participation.
  • Positive screening for alcohol or drugs of abuse, except where a positive drug screen in participants with hepatic impairment can be explained by permitted concomitant medication.
  • Positive pregnancy test in a female participant of childbearing potential.
  • For Cohorts 2 and 3: clinically relevant disease other than hepatic impairment and its associated manifestations that may affect safety, PK interpretation, or Child-Pugh assessment.
  • For Cohorts 2 and 3: potentially infectious liver disease, including hepatitis B or C.
  • For Cohorts 2 and 3: hepatic carcinoma, hepatorenal syndrome, predicted life expectancy of less than 1 year, severe portal hypertension, severe ascites requiring frequent paracentesis, severe hepatic encephalopathy, recent gastrointestinal hemorrhage, or previous kidney, liver, or heart transplantation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cohort 1: No Hepatic Impairment

Participants without hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

Andre navne:
  • VAD044
Eksperimentel: Cohort 2: Mild Hepatic Impairment

Participants with mild hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

Andre navne:
  • VAD044
Eksperimentel: Cohort 3: Moderate Hepatic Impairment

Participants with moderate hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

Andre navne:
  • VAD044

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Area Under the Concentration-time Curve (AUC) from Zero to the Last Quantifiable Concentration (AUC0-tlast) of Engasertib
Tidsramme: Up to Day 12
Up to Day 12
AUC from Zero to Infinity (AUC0-inf) of Engasertib
Tidsramme: Up to Day 12
Up to Day 12
Maximum Plasma Concentration (Cmax) of Engasertib
Tidsramme: Up to Day 12
Up to Day 12

Sekundære resultatmål

Resultatmål
Tidsramme
Amount Excreted (Ae) in Urine from Time Zero to 72 h (Ae0-72)of Engasertib
Tidsramme: Up to Day 4
Up to Day 4
Fraction Excreted (Fe) in Urine from Time Zero to 72 h [Fe (%)] of Engasertib
Tidsramme: Up to Day 4
Up to Day 4
Renal Clearance (CLr) of Engasertib
Tidsramme: Up to Day 4
Up to Day 4
Percentage of Participants who Experienced Teatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Tidsramme: Up to Day 12
Up to Day 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Katarzyna Jarus-Dziedzic, MD, PhD, BioResearch Group Sp. z o.o.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. april 2027

Datoer for studieregistrering

Først indsendt

9. november 2026

Først indsendt, der opfyldte QC-kriterier

9. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ENG-103
  • 2026-526312-37-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner